CD2AP and malignant colon neoplasm: In vitro studies have identified CTL responses to synthetic mutant peptides arising from common cMS mutations, using peripheral blood mononuclear cells from patients with MSI colon cancers[10], [11], [12], [13], [14], [36] and intriguingly, also in healthy individuals with HNPCC[15].